Saturday 17 October 2026
Export BHST’s income statement to Excel — free account
BioHarvest Sciences Inc.
BHST Consumer Defensive Packaged Foods
BioHarvest Sciences Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.5 million, up 37.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3.78%, EPS grew 29.2%, free cash flow fell 64.0% and total debt fell 73.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
1.85
0.15
+8.82%
Follow BHST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.83 | 2.80 | 2.77 | 5.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(23.23) | (71.34) | (42.43) | (78.42) | |
P/B ratio |
3.28 | 4.27 | 3.75 | 21.20 | |
Price to Tangible BV |
3.28 | 4.27 | 3.75 | 21.20 | |
EV/Sales |
1.47 | 2.30 | 2.18 | 4.86 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.11) | (11.25) | (10.39) | (21.60) | |
EV/FCF |
(4.84) | (8.55) | (7.84) | (16.82) | |
Quick Ratio |
1.75 | 2.44 | 3.38 | 1.02 | |
Current Ratio |
2.24 | 2.96 | 3.97 | 1.35 | |
Net Debt/EBITDA |
6.73 | 12.55 | 29.73 | 9.20 | |
Debt/Assets |
5.97% | 5.53% | 5.39% | 17.17% | |
Debt/Equity |
0.13 | 0.11 | 0.10 | 0.78 | |
Asset Turnover |
0.98 | 0.97 | 0.95 | 1.07 | |
Operating CF/Net income |
0.75 | 0.52 | 1.02 | 0.83 | |
Capex/Depreciation |
(1.15) | (1.39) | (1.51) | (1.10) | |
Interest Coverage |
(2.00) | (2.10) | (0.93) | (0.60) | |
Research and Development Expense of Revenue |
18.83% | 16.39% | 14.32% | 15.79% | |
Selling, General and Administrative Expense of Revenue |
67.05% | 64.38% | 55.68% | 55.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.16% | 2.54% | 1.63% | 1.47% | |
Graham Net Nets |
0.02 | 0.06 | 0.09 | (0.06) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.18%) | (13.59%) | (11.75%) | (7.23%) | |
Free Cash Flow Yield |
(16.59%) | (9.60%) | (10.03%) | (5.77%) | |
Revenue per Share |
0.39 | 0.38 | 0.49 | 0.52 | |
Operating CF per Share |
(0.12) | (0.06) | (0.12) | (0.12) | |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.02) | |
Free Cash Flow per Share |
(0.15) | (0.09) | (0.16) | (0.14) | |
Cash per Share |
0.72 | 0.89 | 1.25 | 0.63 | |
Shareholders Equity per Share |
0.87 | 1.02 | 1.38 | 0.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.87 | 1.02 | 1.38 | 0.44 | |
Free Cash Flow |
(3.36) | (1.97) | (2.91) | (2.52) | |
Working Capital |
14.50 | 18.74 | 22.82 | 4.65 | |
Capital Expenditures |
(0.57) | (0.59) | (0.65) | (0.42) | |
Net Current Asset Value |
1.38 | 5.79 | 8.28 | (9.61) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.07 | 0.07 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.33 | 2.71 | 2.36 | 2.23 | |
Average Payables |
3.08 | 3.21 | 3.08 | 3.96 | |
Average Inventory |
4.95 | 4.49 | 4.11 | 3.81 | |
Average Assets |
36.18 | 36.07 | 36.33 | 30.51 | |
Average Common Equity |
7.77 | 11.07 | 13.39 | 5.94 |
Columns are period end dates